Cargando…
Nanotechnology-Based Topical Delivery of Natural Products for the Management of Atopic Dermatitis
Atopic dermatitis (AD) is a chronic eczematous inflammatory disease that may arise from environmental, genetic, and immunological factors. Despite the efficacy of current treatment options such as corticosteroids, such approaches are mainly focused on symptom relief and may present certain undesirab...
Autores principales: | , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10302414/ https://www.ncbi.nlm.nih.gov/pubmed/37376172 http://dx.doi.org/10.3390/pharmaceutics15061724 |
_version_ | 1785065039250587648 |
---|---|
author | Marques, Mário Pedro Varela, Carla Mendonça, Laura Cabral, Célia |
author_facet | Marques, Mário Pedro Varela, Carla Mendonça, Laura Cabral, Célia |
author_sort | Marques, Mário Pedro |
collection | PubMed |
description | Atopic dermatitis (AD) is a chronic eczematous inflammatory disease that may arise from environmental, genetic, and immunological factors. Despite the efficacy of current treatment options such as corticosteroids, such approaches are mainly focused on symptom relief and may present certain undesirable side effects. In recent years, isolated natural compounds, oils, mixtures, and/or extracts have gained scientific attention because of their high efficiency and moderate to low toxicity. Despite their promising therapeutic effects, the applicability of such natural healthcare solutions is somewhat limited by their instability, poor solubility, and low bioavailability. Therefore, novel nanoformulation-based systems have been designed to overcome these limitations, thus enhancing the therapeutic potential, by promoting the capacity of these natural drugs to properly exert their action in AD-like skin lesions. To the best of our knowledge, this is the first literature review that has focused on summarizing recent nanoformulation-based solutions loaded with natural ingredients, specifically for the management of AD. We suggest that future studies should focus on robust clinical trials that may confirm the safety and effectiveness of such natural-based nanosystems, thus paving the way for more reliable AD treatments. |
format | Online Article Text |
id | pubmed-10302414 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-103024142023-06-29 Nanotechnology-Based Topical Delivery of Natural Products for the Management of Atopic Dermatitis Marques, Mário Pedro Varela, Carla Mendonça, Laura Cabral, Célia Pharmaceutics Review Atopic dermatitis (AD) is a chronic eczematous inflammatory disease that may arise from environmental, genetic, and immunological factors. Despite the efficacy of current treatment options such as corticosteroids, such approaches are mainly focused on symptom relief and may present certain undesirable side effects. In recent years, isolated natural compounds, oils, mixtures, and/or extracts have gained scientific attention because of their high efficiency and moderate to low toxicity. Despite their promising therapeutic effects, the applicability of such natural healthcare solutions is somewhat limited by their instability, poor solubility, and low bioavailability. Therefore, novel nanoformulation-based systems have been designed to overcome these limitations, thus enhancing the therapeutic potential, by promoting the capacity of these natural drugs to properly exert their action in AD-like skin lesions. To the best of our knowledge, this is the first literature review that has focused on summarizing recent nanoformulation-based solutions loaded with natural ingredients, specifically for the management of AD. We suggest that future studies should focus on robust clinical trials that may confirm the safety and effectiveness of such natural-based nanosystems, thus paving the way for more reliable AD treatments. MDPI 2023-06-14 /pmc/articles/PMC10302414/ /pubmed/37376172 http://dx.doi.org/10.3390/pharmaceutics15061724 Text en © 2023 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Review Marques, Mário Pedro Varela, Carla Mendonça, Laura Cabral, Célia Nanotechnology-Based Topical Delivery of Natural Products for the Management of Atopic Dermatitis |
title | Nanotechnology-Based Topical Delivery of Natural Products for the Management of Atopic Dermatitis |
title_full | Nanotechnology-Based Topical Delivery of Natural Products for the Management of Atopic Dermatitis |
title_fullStr | Nanotechnology-Based Topical Delivery of Natural Products for the Management of Atopic Dermatitis |
title_full_unstemmed | Nanotechnology-Based Topical Delivery of Natural Products for the Management of Atopic Dermatitis |
title_short | Nanotechnology-Based Topical Delivery of Natural Products for the Management of Atopic Dermatitis |
title_sort | nanotechnology-based topical delivery of natural products for the management of atopic dermatitis |
topic | Review |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10302414/ https://www.ncbi.nlm.nih.gov/pubmed/37376172 http://dx.doi.org/10.3390/pharmaceutics15061724 |
work_keys_str_mv | AT marquesmariopedro nanotechnologybasedtopicaldeliveryofnaturalproductsforthemanagementofatopicdermatitis AT varelacarla nanotechnologybasedtopicaldeliveryofnaturalproductsforthemanagementofatopicdermatitis AT mendoncalaura nanotechnologybasedtopicaldeliveryofnaturalproductsforthemanagementofatopicdermatitis AT cabralcelia nanotechnologybasedtopicaldeliveryofnaturalproductsforthemanagementofatopicdermatitis |